A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00918
- Alkermes Investigational Site
-
San Juan, Puerto Rico, 00926
- Alkermes Investigational Site
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
- Alkermes Investigational Site
-
Springdale, Arkansas, United States, 72764
- Alkermes Investigational Site
-
-
California
-
Anaheim, California, United States, 92805
- Alkermes Investigational Site
-
Cerritos, California, United States, 90703
- Alkermes Investigational Site
-
Culver City, California, United States, 90230
- Alkermes Investigational Site
-
Garden Grove, California, United States, 92845
- Alkermes Investigational Site
-
Glendale, California, United States, 91206
- Alkermes Investigational Site
-
Long Beach, California, United States, 90822
- Alkermes Investigational Site
-
National City, California, United States, 91950
- Alkermes Investigational Site
-
Oakland, California, United States, 94612
- Alkermes Investigational Site
-
Oceanside, California, United States, 92056
- Alkermes Investigational Site
-
Orange, California, United States, 92868
- Alkermes Investigational Site
-
Pico Rivera, California, United States, 90660
- Alkermes Investigational Site
-
Redlands, California, United States, 92374
- Alkermes Investigational Site
-
San Diego, California, United States, 92123
- Alkermes Investigational Site
-
San Diego, California, United States, 92103
- Alkermes Investigational Site
-
Temecula, California, United States, 92591
- Alkermes Investigational Site
-
Torrance, California, United States, 90502
- Alkermes Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20016
- Alkermes Investigational Site
-
-
Florida
-
Lauderhill, Florida, United States, 33319
- Alkermes Investigational Site
-
Miami, Florida, United States, 33136
- Alkermes Investigational Site
-
North Miami, Florida, United States, 33161
- Alkermes Investigational Site
-
Oakland Park, Florida, United States, 33334
- Alkermes Investigational Site
-
Tampa, Florida, United States, 33609
- Alkermes Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Alkermes Investigational Site
-
Augusta, Georgia, United States, 30912
- Alkermes Investigational Site
-
Decatur, Georgia, United States, 30030
- Alkermes Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60640
- Alkermes Investigational Site
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Alkermes Investigational Site
-
-
Mississippi
-
Flowood, Mississippi, United States, 39232
- Alkermes Investigational Site
-
-
Missouri
-
Creve Coeur, Missouri, United States, 63141
- Alkermes Investigational Site
-
O'Fallon, Missouri, United States, 63368
- Alkermes Investigational Site
-
Saint Louis, Missouri, United States, 63128
- Alkermes Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89102
- Alkermes Investigational Site
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- Alkermes Investigational Site
-
Marlton, New Jersey, United States, 08053
- Alkermes Investigational Site
-
-
New York
-
Brooklyn, New York, United States, 11235
- Alkermes Investigational Site
-
Jamaica, New York, United States, 11432
- Alkermes Investigational Site
-
New York, New York, United States, 10032
- Alkermes Investigational Site
-
New York, New York, United States, 10035
- Alkermes Investigational Site
-
Rochester, New York, United States, 14615
- Alkermes Investigational Site
-
Wards Island, New York, United States, 10035
- Alkermes Investigational Site
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Alkermes Investigational Site
-
Dayton, Ohio, United States, 45417
- Alkermes Investigational Site
-
Middleburg Heights, Ohio, United States, 44130
- Alkermes Investigational Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18104
- Alkermes Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78754
- Alkermes Investigational Site
-
Austin, Texas, United States, 78759
- Alkermes Investigational Site
-
Dallas, Texas, United States, 75243
- Alkermes Investigational Site
-
DeSoto, Texas, United States, 75115
- Alkermes Investigational Site
-
Houston, Texas, United States, 77030
- Alkermes Investigational Site
-
-
Washington
-
Bellevue, Washington, United States, 98007
- Alkermes Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has a body mass index (BMI) of 18.0-30.0 kg/m^2, inclusive, at Visit 1 and Visit 2
- Subject meets the DSM-5 criteria for a primary diagnosis of schizophrenia
- Subject is appropriate for outpatient treatment; has no hospitalizations for acute exacerbations of schizophrenia within 6 months before Visit 1
- Subject has maintained a stable body weight (change </= 5%) for at least 3 months prior to Visit 1 based on self-report
- Additional criteria may apply
Exclusion Criteria:
- Subject has any of the following psychiatric conditions per DSM-5 criteria:
- Diagnosis of schizoaffective disorder or bipolar I or II disorder, or current, untreated or unstable major depressive disorder
- Clinically significant cognitive difficulties present within the past 2 years that could interfere with participation in the study
- Drug-induced or toxic psychosis
- Any other psychiatric condition that could interfere with participation in the study
- Subject poses a current suicide risk at Visit 1 or Visit 2 in the opinion of the investigator
- Subject has inflammatory bowel disease or any other gastrointestinal disorder associated with weight loss, anorexia nervosa, or binge eating disorder
- Additional criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ALKS 3831
Administered as a coated bilayer tablet
|
Daily dosing
|
|
Active Comparator: Olanzapine
Administered as a coated bilayer tablet
|
Daily dosing
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent Change From Baseline in Body Weight at Week 24
Time Frame: Baseline and Week 24
|
Baseline and Week 24
|
|
Percentage of Participants With >/= 10% Weight Gain at Week 24
Time Frame: Baseline and Week 24
|
Baseline and Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Participants With >/= 7% Weight Gain at Week 24
Time Frame: Baseline and Week 24
|
Baseline and Week 24
|
|
Number of Participants Experiencing of Adverse Events (AEs)
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Olanzapine
Other Study ID Numbers
Other Study ID Numbers
- ALK3831-A303
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.